Tricida — Investor Presentation (January 2020)
37 slides from Tricida's investor presentation, Jan 13, 2020
Slide 1: Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease
Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease January 2020
Slide 2: Forward Looking Statements
Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statements of historical facts are forward-looking statements as defined under the Federal securities laws. Examples of such statements include our plans, beliefs,
Slide 3: Our Goals for Veverimer
Our Goals for Veverimer* A Drug Candidate for the Treatment of Metabolic Acidosis in Patients with CKD First and ONLY FDA- Disease Improve How the Approved Treatment Modifying Patient Feels and Functions Significant unmet medical Slow CKD progression Enhance physical need to treat metabolic through
Slide 4: 2020 Key Milestones and Activities
2020 Key Milestones and Activities* 1Q – 2020 2Q – 2020 3Q – 2020 4Q – 2020 o FDA Advisory Committee Meeting o Potential FDA o Focus on Launch of Approval of Veverimer Veverimer – Full under the Accelerated Quarter of Veverimer Approval Program Revenue (PDUFA Goal Date of Aug 22) o Build out commerc
Slide 5: Eight Things to Know about Metabolic Acidosis
Eight Things to Know about Metabolic Acidosis
Slide 6: Metabolic Acidosis is Commonly Caused by Kidney Disease
1. Metabolic Acidosis is Commonly Caused by Kidney Disease Diseased Kidneys Lose Capacity to Excrete Acid Serum Bicarbonate Levels Fall acid Normal 22 – 29 Range mEq/L Serum bicarbonate Acid is Diseased kidneys An increase in generated lose capacity acid leads to a Metabolic 12 – <22 Acidosis mEq/L
Slide 7: Metabolic Acidosis is Highly Prevalent in CKD
2. Metabolic Acidosis is Highly Prevalent in CKD ~ 3 Million Patients with Metabolic Acidosis and CKD in the United States ~600,000 ~1.1 Million > % ~1.4 Million 30 18% 9% Stage 3a Stage 3b Stage 4&5 *Stage 5 pre-dialysis patients. Data on file. NHANES 1999-2004 reports prevalence of CKD Stages 3 an
Slide 8: Metabolic Acidosis Can Impact Kidney, Bone and Muscle Health
3. Metabolic Acidosis Can Impact Kidney, Bone and Muscle Health Metabolic Acidosis is Associated with an Increased Risk of CKD Progression and Adverse Effects On Bone and Muscle Reduced Renal Acid Increased Risk of CKD Secretion Leads to Acid Progression and Mortality Buildup Increased Risk of Acid
Slide 9: Metabolic Acidosis is Linked to Worsening Kidney Disease
4. Metabolic Acidosis is Linked to Worsening Kidney Disease Increased Acid Excretion Augmented Ammoniagenesis and Enhanced Proton Secretion Persistent Acid Activation of Retention Metabolic Endothelin 1 (ET-1), Sustained Expression of Aldosterone and Vicious Acidosis ET-1, Angiotensin II Aldosterone
Slide 10: Multiple Academic Studies Show Increasing Serum Bicarbonate Translates to Clinical Benefit
5. Multiple Academic Studies Show that Increasing Serum Bicarbonate Translates to Clinical Benefit Publications Supporting Renal Benefits Publications Supporting Bone and Muscle Benefits 10
Slide 11: CKD Practice Guidelines Recommend Normal Serum Bicarbonate Range
6. CKD Practice Guidelines Recommend Keeping Patients in a Normal Serum Bicarbonate Range “We suggest that in people with CKD and “In CKD Stages 3, 4, and 5, the serum level of serum bicarbonate concentrations total CO2 should be measured. The frequency <22 mmol/L treatment with oral bicarbonate of
Slide 12: Oral Sodium Bicarbonate Not Established Safe and Efficacious – Part 1
7. Oral Sodium Bicarbonate Has Not Been Established to be Safe and Efficacious (Not FDA-Approved) – Part 1 BiCARB Multi-Center, Double-Blind, Placebo Controlled, Randomized Trial • Population: 300 subjects enrolled at 27 • Efficacy Summary study sites in the UK – There is no evidence of a treatment
Slide 13: Oral Sodium Bicarbonate Not Established Safe and Efficacious – Part 2
7. Oral Sodium Bicarbonate Has Not Been Established to be Safe and Efficacious (Not FDA-Approved) – Part 2 Sodium Attenuates the Beneficial Effects of ARBs and ACEi Sodium-Based Alkali Therapy Causes Deleterious Systemic Effects • In the absence of severe dietary NaCl restriction (<10 Low mEq/day),
Slide 14: Metabolic Acidosis is Undertreated
8. Metabolic Acidosis is Undertreated Oral Alkali Treatment Rates Range from 3% to 15% 100% 90% 80% 70% The majority of patients 60% with metabolic acidosis are NOT treated 50% 40% 30% Receiving Receiving Oral Alkali Therapy 20% 15% % of Patients with Metabolic Acidosis %of Patients with Metabolic <
Slide 15: Three Key Takeaways
Three Key Takeaways Metabolic acidosis is common, harmful 1 and needs to be treated Metabolic acidosis is both a complication and 2 an underlying cause of kidney disease progression There is an urgent need for an FDA-approved 3 therapy to treat metabolic acidosis 15
Slide 16: Potential First-in-Class Polymer for Removal of Excess Acid
Potential First-in-Class Polymer Designed to Have High Binding Capacity for the Removal of Excess Acid Veverimer Mechanism of Action Oral Ingestion Acid Binding in GI Tract Cl- Cl- + + + + NH2 NH2 NH3 NH3 NH3 NH3 H+ Cl- Excretion in Veverimer Veverimer Veverimer feces + + + + NH2 NH2 NH3 NH3 NH3 NH3
Slide 17: High Selectivity for Chloride Ions from Built-In Size Exclusion
High Selectivity for Chloride Ions Derived from Built-In Size Exclusion Mechanism GI Anions Ranked by Size The high degree of cross-linking in veverimer provides a Bile Acids size exclusion mechanism Fatty Acids that leads to high Veverimer selectivity for binding chloride (the Citrate smallest anio
Slide 18: Veverimer Disease Modifying Data Published in The Lancet
Veverimer Disease Modifying Data Published in The Lancet Veverimer-Treated Subjects Experienced a Mean Increase from TRCA-301 / TRCA-301E Study Results Baseline in Serum Bicarbonate of 4.5 mEq/L (p<0.0001) Prespecified Time-to-Event Analyses (52 Weeks) 65% Reduction in the Annualized Event Rate for
Slide 19: Veverimer Safety Summary
Veverimer Safety Summary TRCA-301E Long-Term Extension Trial Veverimer (n=114) Placebo (n=82) Discontinued prematurely 2.6% 9.8% Serious adverse events (none assessed to be related 1.8% 4.9% to study drug) Gastrointestinal adverse 21.4% 25.9% events Wesson DE et al., Lancet 2019; 394: 396-406. 19
Slide 20: Summary of TRCA-301 and TRCA-301E Clinical Trials
Summary of TRCA-301 and TRCA-301E Clinical Trials TRCA-301 Results TRCA-301E Results 20
Slide 21: Veverimer Being Reviewed through Accelerated Approval Program
Veverimer is Being Reviewed through the Accelerated Approval Program – PDUFA Goal Date of August 22 Accelerated Approval Veverimer NDA Accepted for Review through Program Requirements the Accelerated Approval Program Increasing blood bicarbonate may Treats a Serious, Life- slow progression to ESRD f
Slide 22: Our Goal is to Launch Veverimer in the United States
Our Goal is to Launch Veverimer in the United States for Patients with CKD and Metabolic Acidosis Treated by Nephrologists 22
Slide 23: Significant US Market Opportunity
Significant US Market Opportunity 3,000,000 Patients with Increased awareness drives higher CKD and metabolic acidosis diagnosis and treatment metabolic acidosis 1,100,000 beyond nephrologists Expansion Patients Under provides additional opportunity Physician Care Focus on patients seen by ~600,000
Slide 24: Patients Treated By a Relatively Small Number of Nephrologists
A High Number of Patients with Metabolic Acidosis Are Treated By a Relatively Small Number of Nephrologists Highly Concentrated Market 100% 80% of Potential Target Patient Population 80% 60% Cumulative % Potential 40% 20% 0% ~5,000 Nephrologists Cumulative % of nephrologists with highest number of p
Slide 25: We Will Target ~5,000 Community Nephrologists at Launch
We Will Target ~5,000 Community Nephrologists at Launch Optimize Reach with 2 Regional Managers, 10 Division Heads and ~85 Sales Representatives # Nephrologist Symphony Health Solutions IDV® 25
Slide 26: Nephrologists Understand Importance of Treating Metabolic Acidosis
Most Community Nephrologists Understand the Importance of Treating Metabolic Acidosis to Slow Kidney Disease Progression Q: Importance of Treating Metabolic Acidosis in Slowing Kidney Disease Progression? 22% 84% 29% 94% 91% 47% Extremely Important 23% Very Important 41% Moderately Important 29% 29%
Slide 27: Expanding our Disease Awareness Campaign
Expanding our Disease Awareness Campaign Website and Neph+ App Digital Ads and Congresses ASN Kidney Week Meeting www.metabolicacidosisinsights.com >1,000 Engagements with HCPs Now ranked 1st on Google search 27
Slide 28: Increasing Awareness through Peer-to-Peer Engagement
Increasing Awareness through Peer-to-Peer Engagement • Metabolic Acidosis Working Group Meeting – 30 key opinion leaders in nephrology – Key takeaway: new evidence supports guideline updates • Publications / presentations on clinical data and complications of metabolic acidosis TRCA-301 Results TRCA
Slide 29: Positive Reaction to Veverimer Profile and Anticipated Adoption
Positive Reaction to Veverimer Profile and Anticipated Adoption Supports Market Opportunity to Address a High Unmet Need Nephrologists Were Asked about Their Nephrologists Were Asked to Estimate Likelihood of Prescribing Veverimer* Veverimer Share at One Year* 79% Would Definitely or Probably Prescr
Slide 30: Engaging with Payers to Facilitate Optimal Coverage
Engaging with Payers to Facilitate Optimal Coverage $$$ $$$ $$$$ $$$ Managed Market Employing Multiple Payer Working Team Actively Avenues for Handling Group Meeting Meeting with Payers Prior Authorizations • Met with 4 payers • Building field-based payer • Mirror nephrologists’ representing over 15
Slide 31: Ongoing Payer Discussions Include Health Impact of Metabolic Acidosis
Ongoing Payer Discussions Include Health Impact of Metabolic Acidosis Supportive Data from Analysis of Major Payer Database Shows Significant Health Impact of Metabolic Acidosis Over a Two-Year Period 3X 3.6X 1.5X Higher Higher Higher Likelihood Likelihood of Likelihood to of Death Starting Dialysis
Slide 32: Ongoing Payer Discussions Include HEOR Analysis
Ongoing Payer Discussions Include Compelling HEOR Analysis Compelling Health Economic Outcomes Research (HEOR) Message for Payers Impact of increase in serum Impact of metabolic acidosis bicarbonate as a continuous comparing all-cause cost in an variable in combined acidotic and acidotic vs. non-aci
Slide 33: Initial Focus on Commercial, Medicare with Subsidy, Medicaid and VA/DOD
Initial Focus will be on Commercial, Medicare with Subsidy, Medicaid and VA/DOD Patients, Representing ~62% of Target Population Anticipated Payer Mix in Target Population 1% VA/ DOD Uninsured5% Cash Medicaid Over half of the initial 10% Medicaid targeted patients with CKD 33% and metabolic acidosis
Slide 34: Opportunity to Achieve Over $2 Billion Peak Revenue in the US
Veverimer Has the Opportunity to Achieve Over $2 Billion Peak Revenue in the US Alone 3,000,000 Potential Peak US Revenue Metrics Patients with CKD and metabolic acidosis Est. WAC price: ~$2,000 - $3,000/month Est. net price (~30% GtN): ~$1,400 - $2,100/month 1,100,000 Patients Under Est. compliance
Slide 35: Veverimer Comprehensive Worldwide Patent Estate
Veverimer Comprehensive Worldwide Patent Estate United States Europe Rest of World • Six issued Orange • Two issued • Issued patents in Australia, Book eligible patents patents Japan and Mexico • Several pending • Several pending • Corresponding pending patent applications patent applications patent
Slide 36: Strong Financial Position
Strong Financial Position ~ $355 million year-end cash, cash equivalents and investments of as of December 31, 2019* $60 million currently drawn under a $200 million debt facility with Hercules (including $20 million drawn in December 2019) – Additional draw down availability of: • $15 million prior
Slide 37: Thank You
THANK YOU [RICIDA